Bringing a new drug from discovery to market is a grueling marathon that typically requires 10–15 years of research, testing, and regulatory approval. According to recent data, clinical development ...

MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock ...

The cells in living organisms are constantly making proteins. Ribosomes, the RNA-protein complexes that make other proteins, ...

A virus relies on the host's translation machinery to replicate itself and become infectious. Translation efficiency ...

mRNA molecule, illustration. [Kateryna Kon/Science Photo Library/Getty Images] Messenger RNA (mRNA) has already transformed medicine, most notably through COVID‑19 vaccines that taught cells to act as ...

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot. Reading time 3 minutes Next-generation vaccines could make the flu season ...

Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...

WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin ...

The U.S. government has awarded Kernal Bio and three other sub-awardees up to $48 million to help advance the biotech’s in vivo mRNA-encoded CAR T-cell program. In an interesting—if not somewhat ...